Pfizer says maternal RSV vaccine prevents infection in infantsPfizer reported topline data from a phase 3 trial of its respiratory syncytial virus vaccine for pregnant women, which showed high vaccine efficacy in newborns.Rose WeldonInfectious Disease News...
It may also be given to pregnant persons to help prevent infection in infants younger than 6 months. The vaccine is given between weeks 32 and 36 of pregnancy, or at least 2 weeks before delivery. Wash your hands often. Wash after you use the bathroom, change a child's diaper, and ...
Vaccine hesitancy has many influences. One often underdiscussed influence is cultural differences regarding vaccines and health care approaches more broadly. During the COVID-19 pandemic, acceptance for the COVID-19 vaccine in White and Asian populations was around 37% and 44% respectively.11In comp...
The design of the RSV F protein to stabilize pre-fusion (pre-F) conformation is a critical advancement in RSV vaccine development, as pre-F form elicits significantly stronger neutralizing activity and better protection against RSV infection and disease progression in both animal models and humans39...
After years of setbacks for RSV research, drugmakers have made big improvements this year. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women. The aim...
[03:50.24]The aim is for the vaccine to pass along protection to their newborns. [03:56.52]I'm Dan Novak. ___ Words in This Story infant— n.a very young child antibody— n.a substance produced by the body to fight disease...
Pfizer's clinical trialresultsfound 69.4% vaccine efficacy in lowering the risk of severe lower respiratory tract illness, through six months after birth. That was well above the minimum criteria to be licensed, the FDA said, though they noted protection against infection is expected to wane as ...
One patient in the vaccine group also experienced GBS. Based on these results, the study investigators concluded that the RSVpreF vaccine was both safe and effective. However, a limitation of the study was that patients who were immunocompromised—a population at risk of severe infection by RSV...
Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted ...
This study offers a solution to the formalin inactivatedrespiratory syncytial virus(FI-RSV)vaccinethat did not protect children, but rather caused severe respiratory illness, vaccine-enhanced respiratory disease (ERD), after infection with RSV.